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Abstract
Introduction: Rheumatoid arthritis (RA) is associated with increased cardiovascular morbidity and mortality
attributed to both classical risk factors and chronic inflammation. We assessed longitudinally the factors associated
with new carotid plaques in nondiabetic RA patients and apparently healthy individuals.
Methods: In our present prospective observational study, carotid plaques were identified by ultrasonography at
baseline and follow-up end, separated by an average of 3.6 ± 0.2 years, in 64 patients (mean age 59.2 ± 12.0 and
disease duration at baseline 7.8 ± 6.2 years, 83% women, clinical and laboratory evaluation every 3 to 6 months). In
a substudy, 35 of the patients were matched 1:1 for traditional cardiovascular risk factors with ‘healthy’ controls and
were studied in parallel.
Results: New atherosclerotic plaques formed in 30% of patients (first plaque in 9%) who were significantly older
than the remaining patients. Tobacco use, blood pressure, body mass index, average cumulative low-density
lipoprotein, high-sensitivity C-reactive protein, erythrocyte sedimentation rate level, RA stage, functional class,
disease duration and treatment modalities during follow-up did not differ significantly between subgroups after
application of the Bonferroni correction. RA was in clinical remission, on average, for approximately 70% of the
follow-up time and was not different between subgroups. Multivariate analysis including all the above parameters
revealed that age (P = 0.006), smoking (P = 0.009) and duration of low-dose corticosteroid use (P = 0.016)
associated independently with new plaque formation. RA patients displayed similar numbers of newly formed
carotid plaques to the tightly matched for traditional cardiovascular risk factors ‘healthy’ controls, although more
patients than controls had carotid plaques at baseline.
Conclusions: Formation of new atherosclerotic plaques in this small cohort of patients with well-controlled RA
depended mainly on traditional cardiovascular risk factors and corticosteroid use, whereas an adverse effect of
residual systemic inflammation was not readily detectable.
Introduction
Rheumatoid arthritis (RA) is an independent risk factor
for cardiovascular disease (CVD) that is associated with
at least a 1.5-fold increased risk for a fatal coronary event
compared to the general population [1]. This is based
predominantly on data derived from epidemiological
studies conducted during the past two or three decades,
which included many RA patients diagnosed and mana-
ged before the era of aggressive, target-driven therapy
with disease-modifying antirheumatic drugs (DMARDs),
including biologic agents [2]. Complementary data deriv-
ing from cross-sectional studies have shown that RA
patients have evidence of advanced preclinical carotid
atherosclerosis compared to healthy controls [3] to a
magnitude similar to that observed in patients with
diabetes mellitus (DM) [4]. High-resolution B-mode
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ultrasonography of the carotid artery provides a noninva-
sive, valid and reproducible method for identifying ather-
osclerotic plaques, which reflect prevalent, clinical or
preclinical CVD and may represent predictors of future
CVD events [5]. Notably, in RA patients without tradi-
tional CVD risk factors or events, an increased intima-
media thickness (IMT) of the common carotid artery and
evidence of focal plaques were each predictive of incident
CVD events [6,7].
There is an increased burden of traditional CVD risk
factors in RA patients [8], including hypertension [9],
dyslipidaemia [10], smoking [11], insulin resistance [12],
obesity and/or altered body composition [13,14] and phy-
sical inactivity [15], but this accounts only partly for the
excess CVD mortality [16]. Because inflammation plays a
major role in the atherosclerotic process [17], interest
has focused on the impact of the systemic inflammatory
burden and chronic activation of the immune system
[18] present in RA [19,20]. Given the paucity of prospec-
tive data, the extent to which traditional CVD risk factors
and RA-related parameters (inflammatory burden, activ-
ity and/or remission and treatment modalities) interact
and/or contribute to atherosclerosis acceleration remains
inconclusive [21]. According to a recent study, both tra-
ditional CVD risk factors and markers of RA severity at
baseline contribute to models predicting cardiovascular
(CV) events in the subsequent 22 months [22].
In the present study, we assessed (1) the factors asso-
ciated with the formation of at least one new carotid pla-
que per subject during the follow-up period in
nondiabetic RA patients and (2) whether the number of
newly formed plaques in these patients differs from the
respective number observed in non-RA subjects carefully
matched for traditional CVD risk factors.
Materials and methods
Study population and design
To address the first objective mentioned above, we used a
unique prospective cohort comprising RA patients who
met the American College of Rheumatology classification
criteria [23] and participated in this observational study.
This convenience sample was composed of RA patients
who initially participated in the cross-sectional study
(from 2006 to 2007) [4], who were asked consecutively to
provide informed consent and were willing and available
to be reassessed after 3 years. Exclusion criteria at base-
line were the presence of CVD (based on positive medical
history, and/or clinical examination, and/or ECG
abnormalities), DM, uncontrolled hypothyroidism, renal
impairment and malignancy or treatment with nonsteroi-
dal anti-inflammatory drugs (NSAIDs). Subclinical caro-
tid atherosclerosis was evaluated at baseline and during
the fourth year after baseline (2009 to 2010). To address
the second objective mentioned above, we used a cohort
of apparently ‘healthy’ control subjects. RA patients were
matched 1:1 with controls for all the traditional CV risk
factors (age ± 1 year, sex, smoking habits, body mass
index (BMI) ± 3 kg/m2, hypertension and/or antihyper-
tensive drug treatment and dyslipidaemia and/or statin
treatment) present not only at baseline but also at the
end of follow-up. Control subjects were recruited among
hospital personnel or patients’ ‘buddies’ and underwent
the same evaluations at baseline and follow-up end.
Matching was possible for 35 RA-control pairs.
The study was subject to Institutional Body Review,
and all subjects provided their informed consent accord-
ing to the Declaration of Helsinki.
Evaluation and management of RA patients
Clinical evaluation and laboratory tests (cholesterol, low-
density lipoprotein (LDL), erythrocyte sedimentation rate
(ESR) and high-sensitivity C-reactive protein (hs-CRP))
were performed at baseline and at every regular follow-
up visit thereafter (every 3 to 6 months), as well as at any
time a patient experienced a disease flare. Rheumatoid
factor (RF), functional status (class I, II, III or IV) [24]
and progression of RA (early, moderate, severe or term-
inal stage) [25] were assessed at baseline for each patient.
At each visit, three blood pressure (BP) measurements
were taken (Omron 705CP; Omron Healthcare, Inc, Lake
Forest, IL, USA) in the right upper limb after 5 minutes
of rest with the subject seated and the arm supported at
heart level, and the average BP was used. In the absence
of antihypertensive treatment, “hypertension” was
defined as the presence of systolic BP (SBP) ≥ 140 mmHg
and/or diastolic BP (DBP) ≥ 90 mmHg [11]. Similarly, in
the absence of lipid-lowering treatment, dyslipidaemia
was defined as LDL ≥ 160 mg/dl [26]. Periods of uncon-
trolled BP and periods of dyslipidaemia (in months) were
recorded and summed for each patient using these cut-
offs. Family history of coronary artery disease (CAD) was
defined as positive if a cardiac event (fatal or nonfatal
myocardial infarction or coronary angioplasty and/or
coronary artery bypass surgery) had occurred before the
age of 55 years in male first-degree relatives and before
the age of 65 years in female first-degree relatives.
Periods of clinical remission of RA during follow-up
were recorded (in months) and summed for each patient.
For this purpose, remission was not defined by the Disease
Activity Score in 28 joints, often used in clinical trials,
which applies for a given day (joint counts) and the pre-
vious week (Visual Analogue Scale), but on the basis of at
least five of the following six criteria being present for at
least 2 months: (1) duration of morning stiffness < 15 min-
utes, (2) no fatigue, (3) no joint pain, (4) no joint tender-
ness and/or pain on motion, (5) no soft-tissue swelling
and (6) ESR < 30 mm/hour for females or < 20 mm/hour
for males [27]. Patients were treated according to
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guidelines for optimal RA control (that is, disease remis-
sion) while avoiding administration of NSAIDs [28].
Assessment of carotid plaque
The presence of atherosclerotic plaques in the carotid
arteries was determined using a 14.0-MHz multifre-
quency linear array probe attached to a high-resolution
ultrasound machine (Vivid 7 Pro; GE Healthcare, Little
Chalfont, Buckinghamshire, UK), based on the interna-
tional recommendations [29]. In each subject, the follow-
ing six sites (three paired left and right segments) were
used for the investigation of atherosclerotic plaques: (1)
at the common carotid artery, defined as the segment 1
cm proximal to carotid dilation; (2) at the carotid bulb,
defined as the segment between the carotid dilation and
carotid flow divider; and (3) at the internal carotid artery,
defined as a 1-cm-long arterial segment distal to the flow
divider. All segments were identified in the transverse
and/or longitudinal planes and scanned from multiple
angles to optimize the detection of unobstructive pla-
ques. Atherosclerotic plaques were defined at baseline or
at follow-up end as focal structures at the far wall that
encroached into the arterial lumen at least 0.5 mm or
50% of the surrounding IMT value or that demonstrated
a thickness > 1.5 mm measured on a digitally stored
image [29]. Baseline images were reevaluated offline
using Artery Measurement Software [30] concurrent
with follow-up images to avoid interpretation bias.
Statistical analysis
Statistical analysis was performed using SPSS version
18.0 software (SPSS, Inc, Chicago, IL, USA), and signifi-
cance was defined as P < 0.05 throughout. Variables were
tested for normality using the Kolmogorov-Smirnov test.
For each patient, the average of values obtained during
the follow-up period (at least seven separate values of
SBP and DBP, LDL, hs-CRP and ESR), the respective
areas under the curve (AUCs) and the HeartScore [31]
were calculated. The results are presented as means ± SD
or as percentages, and non-normally distributed continu-
ous variables are presented as median values with lower
and upper quartiles.
For the first objective, patients who developed new pla-
ques during the follow-up period were compared with
those who did not by using an independent sample t-test,
analysis of variance and the Mann-Whitney U test (com-
parison of continuous variables as appropriate), as well as
the c2 or Kendall’s tau-b test (comparison of noncontinu-
ous variables as appropriate). To find the independent
predictors of new plaque formation in the totality of the
RA sample, we applied binary logistic regression analysis
using both enter and backward methods. The possible
presence of interaction between systemic inflammation
and traditional risk factors was tested by introducing into
the multivariate model the product of hs-CRP with each
classical CV risk factor. For the second objective, the
characteristics of the matched populations at baseline
and at the end of the follow-up period were compared
using a paired t-test and Wilcoxon test. To compare the
progression of the number of plaques within each group,
we used a paired t-test and Wilcoxon test.
Results
Characteristics of patients
As reported elsewhere [4], we cross-sectionally investi-
gated 84 nondiabetic RA patients (mean age 59.2 ± 12.1
years, 70% females). For 64 of them (age 59.2 ± 12.0 years
at baseline, 83% females), a prospective evaluation every 3
to 6 months was possible for 40.8 ± 3.0 months (mean ±
SD). Mean disease duration at baseline was 7.8 ± 6.2 years,
and 65% were RF-positive. Thirty patients (47%) had at
least one carotid plaque at baseline. Hypertension, dyslipi-
daemia, current tobacco use and family history of CAD
were present in 46%, 31%, 34% and 21% of patients,
respectively. Throughout the follow-up period patients
were in remission for a median of 34.1 months (20.7 to
38.4). Cumulative ESR and hs-CRP values for the entire
follow-up period were, on average, 26.7 ± 13.4 mm/hour
and 0.5 mg/dl (0.29 to 1.19), respectively. Myocardial
infarction occurred in one male patient, and one addi-
tional male patient and one female patient underwent car-
otid stenting during follow-up. All three patients remained
in the study, and new plaque formation in the contralat-
eral artery was assessed.
New carotid atherosclerotic plaque formation
At follow-up end, 30% of the patients had developed at
least one new carotid plaque. First plaque was noted in
six (9%) of them. RA-related parameters, including dura-
tion of disease remission and treatment modalities imple-
mented, as well as traditional CV risk factors, statin use
and antihypertensive treatment in subgroups of patients
stratified by the presence of new carotid plaque, are pre-
sented in Table 1. Although 13 of 28 comparisons
reached statistical significance, including smoking,
months of treatment with corticosteroids (between 2.5
and 10 mg prednisolone/day), cumulative number of tra-
ditional risk factors and carotid plaques at baseline (all
P < 0.02), only age was significantly different between
those RA patients who developed new plaque and those
who did not after we applied the Bonferroni correction
for multiple comparisons (P = 0.008).
Thirteen of the sixty-four RA patients were free of tradi-
tional CVD factors: hypertension, dyslipidaemia and
smoking. As expected, they were significantly younger
(47.9 ± 14.3 years) than the remaining patients. None of
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Table 1 Rheumatoid arthritis-related parameters and traditional cardiovascular risk factors in subgroups of
nondiabetic rheumatoid arthritis patients stratified by the presence of at least one new carotid plaque at follow-up
enda
New carotid plaque formation during follow-up
Parameters Yes No
Patient demographics
Total number of patients 19 45
Age at follow-up end (years)b 70.6 ± 6.9 59.2 ± 12.1




Months of follow-up (months) 40.6 ± 3.0 40.9 ± 3.0
RA-related parameters
Duration of disease at follow-up end (years) 9.4 ± 3.9 11.9 ± 6.9
Functional class of disease, n (%)
Class I 12 (63.2) 18 (40.0)
Class II 6 (31.6) 17 (37.8)
Class III 1 (5.3) 9 (20.0)
Class IV 0 (0) 1 (2.2)
Stage of disease, n (%)
Early 6 (31.6) 11 (24.4)
Moderate 12 (63.2) 19 (42.2)
Severe 1 (5.3) 14 (31.1)
Terminal 0 (0) 1 (2.2)
RF-positive, n (%) 13 (68.4) 29 (64.4)
hs-CRP AUC during follow-up (mg/dl × months) 16.6 (12.4, 57.5) 23.8 (12.3, 45.2)
ESR AUC during follow-up (mm/hour × months) 1,121.1 ± 627.6 1,157.0 ± 537.6
Disease-related treatments (months during follow-up)
Nonbiologic DMARDs 38.4 (35.1, 41.4) 40.0 (32.6, 42.5)
Biologic agents 0.0 (0.0, 39.3) 31.6 (0.0, 41.4)
Corticosteroids 40.5 (35.2, 42.3) 33.2 (3.7, 41.7)
Remission during follow-up (months) 36.2 (32.4, 39.1) 31.4 (11.3, 37.3)
Remission during follow-up (% of follow-up time) 90.5 (85.0, 92.9) 84.6 (27.8, 92.6)
Traditional cardiovascular risk factors
Hypertension at baseline, n (%) 12 (66.7) 17 (37.8)
SBP AUC during follow-up (mmHg × months) 5,791.1 ± 634.3 5,416.7 ± 599.6
DBP AUC during follow-up (mmHg × months) 3,491.4 ± 306.5 3,333.9 ± 323.9
Antihypertensive treatment (% follow-up time) 2.3 (0, 2.4) 0 (0, 2.3)
LDL ≥ 160 mg/dl and/or under statin treatment at baseline, n (%) 8 (42.1) 12 (26.7)
LDL AUC during follow-up (mg/dl × months) 5,528.9 ± 1294.1 5,457.7 ± 1377.9
Statin use during follow-up (% follow-up time) 0.0 (0.0, 29.0) 0.0 (0.0, 0.0)
Smoking at end of follow-up, n (%) 7 (36.8) 14 (31.1)
Total years of smoking 30 (0.0, 40.0) 0.0 (0.0, 29.0)
BMI (kg/m2)
BMI at baseline 26.1 ± 3.5 25.9 ± 3.7
BMI at follow-up end 26.0 ± 3.8 26.3 ± 4.4
Positive family history of CAD, n (%) 7 (36.8) 8 (17.8)
Number of CV risk factors, n (%)
0 0 (0) 13 (28.9)
1 9 (47.4) 17 (37.8)
2 7 (36.8) 12 (26.7)
3 3 (15.8) 3 (6.7)
Carotid plaques at baseline, n (%) 14 (73.7) 16 (35.6)
aAUC: area under the curve, BMI: body mass index, CAD: coronary artery disease, CV: cardiovascular, DBP: diastolic blood pressure, ESR: erythrocyte sedimentation
rate, hs-CRP: high-sensitivity C-reactive protein, LDL: low-density lipoprotein, RA: rheumatoid arthritis, SBP: systolic blood pressure. Data are number (%), mean ±
SD or median (lower and upper quartiles). bSignificant difference between subgroups after Bonferroni correction for multiple comparisons (P = 0.0084). All other
comparisons did not reach significance.
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them developed new carotid plaque during follow-up,
although they had disease duration at baseline comparable
with the remaining patients (data not shown).
Factors associated with atherosclerotic plaque formation
We searched for parameters predictive of new carotid
plaque formation by binary logistic regression analysis.
Because of the limited number of RA patients who devel-
oped a new plaque, we evaluated the combined effect of
traditional CV risk by introducing into the models (enter
method) HeartScore together with (one at a time) RA-
related parameters (RF positivity, functional class and
stage of RA at baseline and biologic and nonbiologic
DMARDs). HeartScore at baseline (B = 0.256, P = 0.011)
and months of corticosteroid use during follow-up (B =
0.069, P = 0.013) were independent predictors of new
plaque formation (r2 = 0.345). Because the subgroup of
patients with new atherosclerotic plaque formation was
older by 11 years than the subgroup without, however,
traditional risk factors (for example, longer smoking
duration) may have already had an opportunity to ‘take a
toll’ on the arteries before RA clinically manifested. To
further examine determinants of new carotid plaque for-
mation, we matched patients from these subgroups 1:1
for age (± 3 years) and sex. Among 15 patient pairs, we
found that the only determinant of new plaque formation
was corticosteroid use duration (P = 0.044).
We then investigated the contribution of individual CV
risk factors by multivariate analysis using both enter and
backward methods (Table 2). First, traditional CV risk fac-
tors (age, sex, smoking, BP and BMI) were entered into
the multivariate model (model 1). Only age and total years
of smoking independently predicted new carotid plaque
formation. Second, only parameters related to RA disease
status (RF positivity, functional class and stage of RA at
baseline, percentage in remission during follow-up, and
hs-CRP) were entered into the model (model 2, data not
shown in Table 2). None of these parameters predicted
new carotid plaque formation. Third, in model 3, only
treatment modalities (corticosteroids, biologic and nonbio-
logic DMARDs) were entered into the model. In the sub-
group of patients who developed at least one new carotid
plaque during follow-up, biologic agents were given for a
median of 0.0 (0.0 to 39.3) months and comprised mainly
anti-TNF agents (0.0 to 28.5 months). Cytotoxic T-lym-
phocyte antigen 4 immunoglobulin, IL-6R inhibitor, ana-
kinra and rituximab were also used in isolated patients. It
was found that duration of corticosteroid use was posi-
tively associated with new carotid plaque formation. In
contrast, duration of biologic DMARD use was a negative
independent predictor of new carotid plaque formation.
Therefore, only the independent predictors from models
1, 2 and 3 (that is, age, smoking, corticosteroids and biolo-
gic agents) were entered into a final model. Age, smoking
and corticosteroids remained significant and independent
predictors of new plaque formation. Notably, no interac-
tion between classical CV risk factors and hs-CRP was
found in either model 1 or the final model. No significant
alterations were observed after further adjustment of the
final model for family history for CAD, baseline plaques or
CV risk reduction drugs (statins and antihypertensive
agents).
Comparable new carotid plaque formation in rheumatoid
arthritis and matched controls
Thirty-five pairs of RA patients and non-RA subjects who
were successfully matched 1:1 for all the traditional CV
risk factors (sex, age, smoking, BMI, hypertension and dys-
lipidaemia) and CV risk reduction drugs, both at baseline
and at follow-up end, were included in this analysis (Table
3). The RA subgroup was only in part representative of
the entire cohort, because comparison with the remaining
29 patients showed significantly younger age and signifi-
cantly less baseline carotid plaques. All other RA-related
parameters and CV risk factors were not significantly dif-
ferent (data not shown). After adjustment for age, the dif-
ference in the proportion of patients with plaques at
baseline (that is, 12 of 35 versus 18 of 29 (P = 0.044 before
adjustment)) became nonsignificant (P = 0.325). These 35
RA patients were in remission, on average, for a median of
30.1 months (11.1 to 38.3), that is, 84.1% (26.3 to 92.4) of
the follow-up period, whereas the average cumulative
values throughout the follow-up for ESR and hs-CRP were
27.4 ± 13.8 mm/hour and 0.3 mg/dl (0.1 to 0.6), respec-
tively. In total during follow-up, these patients had
received 23.0 months (0.0 to 41.5) of treatment with biolo-
gic agents, 30.0 months (0.0 to 41.6) of methotrexate ther-
apy and 37.3 months (15.1 to 42.7) of corticosteroid
treatment (always < 10 mg prednisolone/day).
As shown in Figure 1, despite the fact that more
patients had carotid plaques at baseline (34% versus
20%, albeit not reaching significance owing to sample
size), only six RA patients developed at least one new
plaque (two of them had no plaque at all at baseline)
compared with five control subjects (four of them had
no plaque at baseline) (relative risk = 1.20, 95% CI 0.35
to 4.27, P = 0.743). Collectively, the number of plaques
per subject increased significantly in both groups during
follow-up (from 0.26 ± 0.56 to 0.51 ± 0.88 plaques per
subject in the control group, P < 0.001; from 0.51 ±
0.81 to 0.71 ± 1.0 plaques per subject in the RA group,
P < 0.017). The change in plaques per subject between
the groups was equal: 0.24 ± 0.66 versus 0.20 ± 0.47,
respectively (P = 0.761).
Discussion
In this prospective, longitudinal study, we examined fac-
tors leading to new carotid plaque formation in
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Table 2 Multivariate models predicting new carotid plaque formation in nondiabetic patients with rheumatoid
arthritis over 3.6 ± 0.2 yearsa
New carotid plaque formation during
follow-up (yes vs no)
Parameters b coefficient P value Odds ratio (95% CI)
Model 1: traditional CV risk factors (r2 = 0.0453)
Age at follow-up end (years) 0.146 0.004 5.752b (1.770 to 18.694)
Sex 0.038 0.970 0.963b (0.134 to 6.927)
Total years of smoking (at follow-up end) 0.051 0.023 2.628b (1.145 to 6.029)
SBP AUC (mmHg × months) 0.001 0.346 1.495b (0.648 to 3.449)
LDL AUC (mg/dl × months) 0.000 0.126 0.507b (0.212 to 1.211)
BMI (at follow-up end) 0.088 0.356 1.445b (0.661 to 3.160)
Model 3 RA treatment (months of treatment during follow-up) (r2 = 0.248)
Corticosteroids 0.067 0.016 3.058 (1.231 to 7.593)
Biologic agents -0.035 0.046 0.502 (0.255 to 0.987)
Nonbiologic DMARDs -0.017 0.477 0.802 (0.437 to 1.473)
Final model (r2 = 0.559)c
Age at follow-up end (years) 0.136 0.006 5.098 (1.599 to 16.250)
Total years of smoking (at follow-up end) 0.055 0.009 2.875 (1.305 to 6.335)
Corticosteroids (months during follow-up) 0.086 0.016 4.170 (1.299 to 13.385)
Biologic agents (months during follow-up) -0.033 0.118 0.520 (0.230 to 1.180)
aAUC: area under the curve, BMI: body mass index, CV: cardiovascular, DMARDs: disease modifying antirheumatic drugs, LDL: low-density lipoprotein, RA:
rheumatoid arthritis, SBP: systolic blood pressure. cOnly the variables from models 1 to 3 that predicted new plaque formation were used in the final model.
Model 2 is described in the text only. bThe odds ratio for the continuous values was assessed for 1 SD increase and so is provided by exp(b*SD) (SD for age 12.0,
for total years of smoking 19.15, for SBP (AUC) 629.10, for LDL (AUC) 1343.77, for BMI 4.25, for corticosteroid treatment (months during follow-up) 16.60, for
biologic agents received (months during follow-up) 19.90, for nonbiologic DMARDs (months during follow-up) 13.20). Dependent variable 0 is subjects with no
new plaque (n = 45), variable 1 is subjects with at least one plaque (n = 19) at the end of follow-up (binary logistic regression analysis using enter method is
presented, and identical results in all models were obtained using the backward method).
Table 3 Characteristics of 35 nondiabetic rheumatoid arthritis patients (29 women, 11 with hypertension, 10 with
dyslipidaemia, 11 smokers) who were matched 1:1 with ‘healthy’ control subjects for sex, age (59.6 ± 11.4 years) and
other traditional cardiovascular risk factors present both at baseline and at follow-up enda
Parameters Matched ‘healthy’ control subjects Subgroup of 35 RA patients
Number of patients 35 35
Follow-up (months) 40.4 ± 3.4 41.4 ± 3.3
hs-CRP (mg/dl)
Baseline 0.1 (0.05, 0.2) 0.3 (0.2, 0.6)
Follow-up end 0.2 (0.08, 0.3) 0.4 (0.2, 0.8)
Traditional CV risk factors
Hypertension (mmHg)
SBP baseline 122.7 ± 21.0 127.0 ± 20.0
SBP follow-up end 123.6 ± 19.1 128.6 ± 13.9
DBP baseline 75.6 ± 12.0 76.9 ± 9.5
DBP follow-up end 75.9 ± 8.9 80.4 ± 7.5
Dyslipidaemia (mg/dl)
LDL baseline 141.3 ± 42.6 136.4 ± 35.6
LDL follow-up end 128.3 ± 31.0 116.2 ± 34.0
Smoking
Pack-years at baseline 0.0 (0.0, 35.0) 0.0 (0.0, 21.4)
Pack-years during follow-up 0.0 (0.0, 3.0) 0.0 (0.0, 1.5)
BMI (kg/m2)
Baseline 25.3 ± 4.3 26.5 ± 4.0
Follow-up end 25.5 ± 4.1 26.9 ± 4.7
aBMI: body mass index, CV: cardiovascular, DBP: diastolic blood pressure, hs-CRP: high-sensitivity C-reactive protein, LDL: low-density lipoprotein, SBP: systolic
blood pressure. Paired t-tests and Wilcoxon tests were used for all comparisons of the matched groups as appropriate. Variables are expressed as mean ± SD or
as median (lower and upper quartiles). Comparisons between subgroups after Bonferroni correction did not reach significance.
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nondiabetic patients with RA without CVD at baseline.
As recently reported, carotid atherosclerosis predicts
future coronary events in RA, whereas those patients
with carotid plaques, multiple CV risk factors (particu-
larly DM or hypertension), many swollen joints and a
high cumulative dose of glucocorticoids, as well as male
RA patients, are at even higher risk [7]. We focused on
new carotid plaque formation and not on IMT progres-
sion, although both biomarkers have been associated
with CV events in RA and non-RA populations and may
have additive predictive value [6,32]. Our decision to
exclude IMT from the analysis was based on the fact
that, though focal plaque is the direct manifestation of
atherosclerosis, IMT is considered a surrogate not only
of diffuse atherosclerosis but also of medial hypertrophy,
unrelated to atherosclerosis, that is driven primarily by
hypertension [32].
Our study produced three main novel findings which
were consistently verified by different statistical
approaches. First, in well-treated RA patients in clinical
remission for more than two-thirds of the follow-up per-
iod, new carotid plaque formation was predominantly
associated with traditional CVD risk factors. Second, of all
RA-related parameters evaluated, only chronic corticoster-
oid use was independently associated with new carotid
plaque formation. Third, over an average 3.5 years follow-
up period, the number of new carotid plaques in the sub-
group of RA patients and the tightly matched for tradi-
tional CVD risk factors non-RA subjects, was similar.
In the present study, a relatively small sample size was
available, probably resulting in insufficient statistical
power to detect small differences, especially at baseline,
between patients with or without new plaque formation
during follow-up. Another limitation is the fact that we
focused solely on new plaque formation and did not
assess the progression of preexisting plaques. Such
assessments ideally require three-dimensional models
that were not available to us, whereas the potential
error that would have been introduced by the available
two-dimensional models might have been too large.
Figure 1 Comparable new carotid plaque formation in rheumatoid arthritis patients and matched controls. New carotid plaque
formation during a mean (± SD) of 3.4 ± 0.3 years in 35 rheumatoid arthritis (RA) patients matched 1:1 with 35 ‘healthy’ subjects for all
traditional cardiovascular risk factors at baseline and at the end of follow-up. Although at baseline almost twice as many RA patients as controls
presented with at least one carotid plaque, the number with new carotid atherosclerotic plaque formation was similar to that of controls (P =
0.743).
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Cross-sectional studies have shown that the severity of
inflammatory burden in long-standing RA measured by
CRP, as well as disease duration, are associated with
increased preclinical atherosclerosis in patients without
traditional CVD risk factors [33]. In the present prospec-
tive study, however, we did not observe any association
between new carotid plaque formation and RA disease-
related parameters, including CRP and ESR levels. We
think that, in a prospective study, the influence of
patients’ characteristics at baseline is less important than
those present during the follow-up period. The lack of
such an association may be explained by the low residual
inflammation present in our optimally treated patient
cohort during the follow-up period as well as by the rela-
tively high burden of traditional CV risk factors in the
present cohort, which constituted a typical RA popula-
tion. All patients were managed according to the latest
approaches of treating to target (that is, disease remis-
sion) with very frequent follow-up, rapid escalation of
disease-modifying therapy and unrestricted access to bio-
logic agents (given in 52% of patients), thus resulting in
clinical remission for more than two-thirds of the follow-
up time. As most recently reported in another prospec-
tive study assessing longitudinal predictors of progression
of carotid atherosclerosis in RA, inflammation was
indeed a contributor. However, the probability of athero-
sclerosis progression was minimal up to an average CRP
threshold of 12 mg/L, whereas, more importantly, the
average CRP (median of cumulative average during study
period of 3.1 mg/L) in nondiabetic RA patients was not
associated with carotid atherosclerosis progression [34].
The finding that the formation of new carotid plaques
in patients with well-controlled RA depends mainly on
traditional CVD risk factors was reproduced in the com-
parative cohort study. In this comparative study, patients
had higher BP than controls by almost 5 mmHg, yet they
developed a similar number of new plaques over a 3.5-
year period. Because the younger age of patients in the
RA matched population versus the remaining patients
could constitute a selection bias, part of the results may
not be representative and thus cannot be extrapolated to
other age groups.
The findings presented herein add credence to the cur-
rent European Union League Against Rheumatism guide-
lines on CVD risk management in RA [1]. Because our
present study was conducted before the publication of
these guidelines, our patients did not receive aggressive
CVD risk reduction management. Smoking, which has a
higher prevalence in Greece than in other European
Union countries [35], and age were the main factors
defining the new carotid plaque formation in the present
population, as expected in non-RA populations [36,37].
This finding clearly shows the need to optimally control
classical CVD risk factors in RA patients, factors which
are often neglected in everyday clinical practice. Of note,
no interaction between inflammation and classical CVD
risk factors and no synergy between them were found.
Also, we did not find any interaction between age- and
RA-related parameters (inflammation or drugs) regarding
their effect on new plaque formation. However, since the
age at onset of RA was greater in patients who developed
new plaques than in those who did not (61.2 ± 7.8 versus
47.3 ± 12.7 years of age respectively, P < 0.001), it is pos-
sible that older arteries may also respond less well to
inflammatory burden and/or steroids and hence the pro-
cess of atherosclerosis may be accelerated.
In contrast to the known detrimental role of high-dose
corticosteroids in CVD risk, until recently there was no
clear evidence for the role of a chronic low daily dose of
corticosteroids in patients with inflammatory arthritis
[1,9,10]. In general, the net effect of corticosteroids on
vascular function in chronic inflammatory disease is
obscure [38]. As reported by Evans et al., higher cumula-
tive glucocorticoid dose does confer a higher risk of
acute coronary syndromes in RA [7]. Even more recently,
Giles et al. reported prospective data suggesting that sub-
clinical carotid atherosclerosis progression in RA is
potentially modified detrimentally by cumulative predni-
sone exposure [34]. Our results also suggest that low
doses of corticosteroids influence significant new plaque
formation in RA. It should be noted, however, that these
are not randomised study-derived data and may thus
represent a low level of proof. Moreover, a detrimental
effect of corticosteroids is a confounding factor by indica-
tion, because it could reflect higher disease activity and
may be associated with RA severity [39].
Although biologic therapies appear to decrease the risk
of CVD events in RA patients [40], inconsistent data have
been reported in several papers on the effects of biologics,
primarily TNF blockers, on carotid atherosclerosis,
depending on the treatment duration and clinical efficacy
of treatment [41,42]. Whether the positive effect of these
drugs is related to their anti-inflammatory actions, leading
to a decreased risk of unstable plaques, rather than to an
effect on the size of carotid IMT deserves further studies.
In the initial multivariate analysis, we found a marginally
significant beneficial effect of biologic DMARDs on the
atherosclerotic process, but the significance was lost in the
final model (Table 2). Other prospective observations sug-
gest that subclinical carotid atherosclerosis progression in
RA is potentially modified favourably by TNF inhibitors
[34]. Taken together, these data imply that particular treat-
ment modalities that induce disease remission, such as
corticosteroids and TNF inhibitors, may be very important
or even more important than disease remission per se as
far as the subclinical atherosclerosis in RA is concerned.
Zampeli et al. Arthritis Research & Therapy 2012, 14:R44
http://arthritis-research.com/content/14/2/R44
Page 8 of 10
Conclusion
Formation of new atherosclerotic plaques in this small
cohort of optimally treated patients with well-controlled
RA depended on traditional CVD risk factors and to a les-
ser extent on corticosteroid use, whereas an adverse effect
of the residual systemic inflammation was not readily
detectable. Therefore, optimal RA management should
aim to achieve not only sustained disease remission but
also successful traditional CVD risk reduction, and this
may have implications in terms of drug regimen selection.
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